A study in the September issue of the Journal of Clinical Sleep Medicine suggests that suvorexant 20/15 mg improved sleep onset and maintenance over 3 months of nightly treatment and was generally safe and well tolerated. The researchers’s concluded the analysis of this study validates orexin receptor antagonism as a novel therapeutic approach for treating insomnia.
Study treating insomnia patients with suvorexant shows success
2016-10-13T00:00:00+00:00 October 13th, 2016|Research|
November 1st, 2018 | 0 Comments
June 22nd, 2018 | 0 Comments
April 20th, 2018 | 0 Comments